Results 31 to 40 of about 16,733 (229)

Estimating the Value of Aztreonam-Avibactam in Treating Metallo-beta-Lactamase-Producing Enterobacterales Infections in Spain Using the STEDI AMR Value Framework. [PDF]

Infect Dis Ther
Antimicrobial resistance; Carbapenem-resistance; Cost effectivenessResistencia antimicrobiana; Resistencia a carbapenémicos; Coste-efectividadResistència antimicrobiana; Resistència a carbapenèmics; Cost-efectivitatIntroduction Treatments for serious ...
Ferrer R, Luque S, Martínez-Martínez L, de Lossada A, Maroto-Diaz M, Moya-Alarcón C, de Ceano-Vivas MC, Moreno Y, Dennis J, Nikolova S, Zormpas E, Broughton E, Gheorghe M.   +12 more
europepmc   +3 more sources

International circulation of aztreonam/avibactam-resistant NDM-5-producing Escherichia coli isolates: successful epidemic clones. [PDF]

Journal of Global Antimicrobial Resistance, 2021
Habib, A., Nordmann, P., Poirel, L., Ruppé, E., Sadek, M., Zahra, R.   +5 more
core   +4 more sources

Activity of aztreonam/avibactam and ceftazidime/avibactam against Enterobacterales with carbapenemase-independent carbapenem resistance.

International Journal of Antimicrobial Agents
Enterobacterales with carbapenemase-independent resistance to carbapenems are sometimes being selected during therapy and, on rare occasions, cause outbreaks.
S. Mushtaq, A. Vickers, N. Woodford, D. M. Livermore   +3 more
semanticscholar   +5 more sources

First Clinical Application of Aztreonam-Avibactam in Treating Carbapenem-Resistant Enterobacterales: Insights from Therapeutic Drug Monitoring and Pharmacokinetic Simulations. [PDF]

J Pers Med
Background: A novel fixed combination of aztreonam (ATM) and avibactam (AVI) offers promising potential to treat infections with carbapenem-resistant Enterobacterales (CRE) producing metallo-β-lactamases (MBL).
Hölsken O, Sponheuer K, Weber F, Martens-Lobenhoffer J, Bode-Böger SM, Kloft C, Treskatsch S, Angermair S.   +7 more
europepmc   +5 more sources

Antimicrobial susceptibility of enterobacterales causing bloodstream infection in United States medical centres: comparison of aztreonam-avibactam with beta-lactams active against carbapenem-resistant enterobacterales

BMC Infectious Diseases
Background Bloodstream infection (BSI) is associated with poor outcomes especially when effective antimicrobial therapy and control of infection source are delayed.
Helio S. Sader, John H. Kimbrough, Rodrigo E. Mendes, Mariana Castanheira   +3 more
doaj   +2 more sources

Cost-Effectiveness Analysis of Aztreonam-Avibactam (ATM-AVI) Versus Colistin + Meropenem (COL + MER) for the Treatment of Infections Caused by Metallo-β-Lactamase (MBL)-Producing Enterobacterales in Italy. [PDF]

Pharmacoeconomics
Aztreonam-avibactam (ATM-AVI) is a novel combination antibiotic approved in Europe for the treatment of complicated intra-abdominal infection, hospital-acquired pneumonia, including ventilator-associated pneumonia; complicated urinary tract infection ...
Falcone M, Bao X, Woodcock F, Di Virgilio R, Vidal Pereira MA, Kantecki M, Gheorghe M.   +6 more
europepmc   +2 more sources

Aztreonam plus ceftazidime-avibactam as treatment of NDM-1-producing Klebsiella pneumoniae bacteraemia in a neutropenic patient: Last resort therapy? [PDF]

Journal of Global Antimicrobial Resistance, 2020
Objectives: We report the successful treatment of a bloodstream infection caused by Klebsiella pneumoniae harbouring NDM-1 using aztreonam-ceftazidime-avibactam in a neutropenic patient in whom colistin and meropenem therapy had previously failed ...
Paola Bocanegra-Ibarias, Adrián Camacho-Ortiz, Elvira Garza-González, Samantha Flores-Treviño, Hyojin Kim, Eduardo Perez-Alba   +5 more
doaj   +3 more sources

Activity of Aztreonam/Avibactam and Recently Approved β-Lactamase Inhibitor Combinations against Enterobacterales and Pseudomonas aeruginosa from Intensive Care Unit and Non-Intensive Care Unit Patients

Antibiotics
We evaluated the activities of aztreonam/avibactam and recently approved β-lactamase inhibitor combinations (BLICs) to compare the antimicrobial susceptibility patterns of Enterobacterales and Pseudomonas aeruginosa isolated from intensive care unit (ICU)
Helio S. Sader, Rodrigo E. Mendes, John H. Kimbrough, Cory M. Hubler, Mariana Castanheira   +4 more
doaj   +2 more sources

P-1213. Optimizing the synergy between Aztreonam & Avibactam for NDM plus OXA48 producing Carbapenem resistant Klebsiella pneumoniae infections: an innovative infusion method [PDF]

Open Forum Infect Dis
Background Ceftazidime-avibactam (CAZ AVI) along with aztreonam (ATM) is used off-label for NDM+OXA48 producing carbapenem resistant Klebsiella pneumoniae (CR Kp).
Rajeev Soman, Aashna Gandhi, Noopur Kedare, Geethu Joe, Saiprasad Patil, A. Pednekar, H. Barkate   +6 more
europepmc   +2 more sources

P-1509. In Vitro Activity of Aztreonam-Avibactam Against Enterobacterales Isolated from Pediatric and Adult Patients Collected During the ATLAS Global Surveillance Program, 2018-2022 [PDF]

Open Forum Infect Dis
Background The spread of antimicrobial resistance among clinically isolated Enterobacterales (Eba) is a threat to public health. Aztreonam (ATM) is a monobactam stable against hydrolysis by metallo-β-lactamases (MBLs) and avibactam (AVI) inhibits class A,
M. Estabrook, Julie Dickson, G. Stone, Katherine Perez, Daniel F. Sahm   +4 more
europepmc   +2 more sources